Table 2.

Sex, age, and race adjusted standardized incidence ratios (SIRs) for selected cancers among a cohort of female and male patients with rheumatoid arthritis, California, 1991–2002 (n = 84,475)

Cancer type	Females (n = 65,236)				Males (n = 19,239)
	Observed	Expected	SIR	95% C	Observed	Expected	SIR	95% CI
Breast	842	1343.5	0.63	0.59–0.67
Ovary	89	142.3	0.63	0.50–0.77
Uterus	126	237.3	0.53	0.44–0.63
Vagina/vulva	56	56.6	0.99	0.75–1.29
Cervix	47	1100	0.43	0.31–0.57
Prostate					407	609.6	0.67	0.60–0.74
Lung	762	593.7	1.28	1.19–1.38	416	252.3	1.65	1.49–1.81
Esophagus	27	25.3	1.07	0.70–1.55	36	20.3	1.78	1.24–2.46
Stomach	72	67.1	1.07	0.84–1.35	41	36.0	1.14	0.82–1.54
Colon/rectum	415	545.5	0.76	0.69–0.84	137	196.7	0.70	0.58–0.82
Liver	36	25.5	1.41	0.99–1.96	32	17.3	1.85	1.26–2.6 1
Pancreas	115	117.0	0.98	0.67–1.03	35	35.9	0.97	0.68–1.36
Bladder	90	107.3	0.84	0.74–1.14	108	112.7	0.96	0.79–1.16
Kidney	82	69.6	1.18	0.94–1.46	43	38.7	1.11	0.80–1.50
Thyroid	26	37.1	0.70	0.46–1.03	3	5.8	0.52	0.11–1.52
Brain/CNS	29	39.3	0.74	0.49–1.06	10	15.8	0.63	0.30–1.16
Non-Hodgkin 's lymphoma	208	151.9	1.37	1.19–1.57	117	56.6	2.07	1.71–2.48
Hodgkins disease	15	9.2	1.62	0.91–2.68	10	3.6	2.76	1.32–5.08
Leukemia	110	86.9	1.27	1.03–1.51	68	41.1	1.65	1.29–2.07
		951.6
Myeloma	41	51.6	0.79	0.57–1.08	23	19.3	1.19	0.75–1.78
Melanoma	107	170.5	0.63	0.51–0.76	77	96.3	0.80	0.63–1.00